Literature DB >> 9798194

Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis.

S M Whitcup1, U Pleyer, J C Lai, S Lutz, M Mochizuki, C C Chan.   

Abstract

PURPOSE: Liposome preparations of FK506 improve the penetration of topically administered drug into the aqueous humor. The purpose of the experiment was to compare topically administered highdose oil-dissolved FK506 (OD-FK506) and low-dose liposome-bound FK506 (LB-506) for the treatment of endotoxin-induced uveitis (EIU).
METHODS: Endotoxin-induced uveitis was produced in female Lewis rats with Salmonella typhimurium endotoxin. Four hours prior to endotoxin injection, one eye received 20 mul eyedrops every four hours containing either high-dose OD-FK506 at 3 mg/ml (N = 20), low-dose LB-FK506 at 0.16 mg/ml (N = 19), prednisolone acetate 1% (N = 20), or empty liposomes (N = 20). Eyes were enucleated 24 hours after endotoxin injection and inflammatory cells were counted on histologic sections by two masked observers.
RESULTS: The mean number of infiltrating inflammatory cells per section +/- S.E.M. was 127.8 +/- 20.1, 76.8 +/- 16.7, 75.0 +/- 19.1, and 3.6 +/- 0.4 for animals treated with empty liposomes, LB-FK506, OD-FK506, and prednisolone acetate, respectively. The difference in inflammation between the empty liposome controls and the LB-FK506- and OD-FK506-treated animals was statistically significant (p = 0.03 and p = 0.02, respectively). The difference in inflammation between the high-dose OD-FK506- and low-dose LB-FK506-treated animals was not statistically significant (0 = 0.94).
CONCLUSION: In this study, low-dose LB-FK506 and high-dose (OD-FK506) were both effective in inhibiting EIU. Higher concentrations of LB-FK506 are being developed and should augment the therapeutic effect of topical FK506.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798194     DOI: 10.1076/ocii.6.1.51.8079

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  10 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis.

Authors:  Eun Hye Ryu; Joung Mok Kim; Pradnya M Laddha; Eui-Sang Chung; Tae-Young Chung
Journal:  Korean J Ophthalmol       Date:  2012-07-24

3.  Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; M Ferlito; G M Campo; M Arlotta; S Grimaldi; C Quartarone; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis.

Authors:  Tais Hitomi Wakamatsu; Mari Tanaka; Yoshiyuki Satake; Murat Dogru; Kazumi Fukagawa; Ayako Igarashi; Hiroshi Fujishima
Journal:  Mol Vis       Date:  2011-04-13       Impact factor: 2.367

5.  Aqueous humor and serum penetration of tacrolimus after topical and oral administration in rats: an absorption study.

Authors:  F Nilüfer Yalçindağ; Figen Batioğlu; Nuray Ari; Ozden Ozdemir
Journal:  Clin Ophthalmol       Date:  2007-03

Review 6.  Topical tacrolimus in anterior segment inflammatory disorders.

Authors:  Samir S Shoughy
Journal:  Eye Vis (Lond)       Date:  2017-03-09

7.  Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis.

Authors:  Chee Wai Wong; Bertrand Czarny; Josbert M Metselaar; Candice Ho; Si Rui Ng; Amutha Veluchamy Barathi; Gert Storm; Tina T Wong
Journal:  Sci Rep       Date:  2018-04-26       Impact factor: 4.379

8.  Aqueous penetration of topical tacrolimus.

Authors:  Samir S Shoughy; Faisal M Aljassar; Khalid F Tabbara
Journal:  Am J Ophthalmol Case Rep       Date:  2020-01-17

9.  Development and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop.

Authors:  Xurxo García-Otero; Victoria Díaz-Tomé; Rubén Varela-Fernández; Manuel Martín-Pastor; Miguel González-Barcia; José Blanco-Méndez; Cristina Mondelo-García; Maria A Bermudez; Francisco Gonzalez; Pablo Aguiar; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2021-01-23       Impact factor: 6.321

10.  Inhibition of Neovascularization and Inflammation in a Mouse Model of Corneal Alkali Burns Using Cationic Liposomal Tacrolimus.

Authors:  Xueqi Lin; Xuewen Yu; Xiang Chen; Siting Sheng; Jingwen Wang; Ben Wang; Wen Xu
Journal:  Front Bioeng Biotechnol       Date:  2021-12-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.